Perturbation of the c-Myc-Max Protein-Protein Interaction via Synthetic α-Helix Mimetics

Journal of Medicinal Chemistry

Volumn 58, Issue 7, 2015, Pages 3002-3024

  Jung, Kwan Young ^a   Wang, Huabo ^b   Teriete, Peter ^c   Yap, Jeremy L ^a   Chen, Lijia ^a   Lanning, Maryanna E ^a   Hu, Angela ^b   Lambert, Lester J ^c   Holien, Toril ^d   Sundan, Anders ^d   Cosford, Nicholas D P ^c   Prochownik, Edward V ^b   Fletcher, Steven ^a,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c BURNHAM INSTITUTE   (United States)

^d NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^e UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (BENZYLOXY) 4 (3 ISOBUTOXY 4 NITROBENZAMIDO)BENZOIC ACID; 3 ISOBUTOXY 4 (3 BENZYLOXY 4 NITROBENZAMIDO)BENZOIC ACID; 3 ISOBUTOXY 4 (3 ISOBUTOXY 4 NITROBENZAMIDO)BENZOIC ACID; 3 ISOBUTOXY 4 (4 NITROBENZAMIDO)BENZOIC ACID; 3 ISOBUTOXY 4 [3 (NAPHTHALEN 1 YLMETHOXY) 4 NITROBENZAMIDO]BENZOIC ACID; 3 ISOBUTOXY 4 [4 NITRO 3 (PYRIDIN 2 YLMETHOXY)BENZAMIDO]BENZOIC ACID; 3 ISOPROPOXY 4 (3 ISOPROPOXY 4 NITROBENZAMIDO)BENZOIC ACID; 3 METHOXY 4 (3 METHOXY 4 NITROBENZAMIDO)BENZOIC ACID; 4 (3 ISOBUTOXY 4 NITROBENZAMIDO) 3 (PYRIDIN 2 YLMETHOXY)BENZOIC ACID; 4 (3 ISOBUTOXY 4 NITROBENZAMIDO) 3 (PYRIDIN 3 YLMETHOXY)BENZOIC ACID; 4 (3 ISOBUTOXY 4 NITROBENZAMIDO) 3 (PYRIDIN 4 YLMETHOXY)BENZOIC ACID; 4 (3 ISOBUTOXY 4 NITROBENZAMIDO)BENZOIC ACID; 4 (4 NITROBENZAMIDO)BENZOIC ACID; 4 [3 [(2,3 DIHYDRO 1H INDEN 2 YL)OXY] 4 NITROBENZAMIDO] 3 ISOBUTOXYBENZOIC ACID; ANTINEOPLASTIC AGENT; MAX PROTEIN; METHYL 3 (BENZYLOXY) 4 (3 BENZYLOXY 4 NITROBENZAMIDO)BENZOATE; METHYL 3 (BENZYLOXY) 4 (3 ISOPROPOXY 4 NITROBENZAMIDO)BENZOATE; METHYL 3 (BENZYLOXY) 4 [3 (NAPHTHALEN 1 YLMETHOXY) 4 NITROBENZAMIDO]BENZOATE; METHYL 3 BENZYLOXY 4 (3 ISOBUTOXY 4 NITROBENZAMIDO)BENZOATE; METHYL 3 ISOBUTOXY 4 (3 ISOBUTOXY 4 NITROBENZAMIDO)BENZOATE; METHYL 3 ISOBUTOXY 4 (3 ISOPROPOXY 4 NITROBENZAMIDO)BENZOATE; METHYL 3 ISOBUTOXY 4 [3 (NAPHTHALEN 1 YLMETHOXY) 4 NITROBENZAMIDO]BENZOATE; METHYL 3 [(2,3 DIHYDRO 1H INDEN 2 YL)OXY] 4 (3 ISOPROPOXY 4 NITROBENZAMIDO)BENZOATE; METHYL 3 [(2,3 DIHYDRO 1H INDEN 2 YL)OXY] 4 [3 (NAPHTHALEN 1 YLMETHOXY) 4 NITROBENZAMIDO]BENZOATE; METHYL 4 [3 (BENZYLOXY) 4 NITROBENZAMIDO] 3 [(2,3 DIHYDRO 1H INDEN 2 YL)OXY]BENZOATE; METHYL 4 [3 [(2,3 DIHYDRO 1H INDEN 2 YL)OXY] 4 NITROBENZAMIDO] 3 ISOBUTOXYBENZOATE; MYC PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; HELIX LOOP HELIX PROTEIN; MAX PROTEIN, HUMAN; MOLECULAR LIBRARY;

ACYLATION; ALPHA HELIX; ARTICLE; BINDING SITE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CITRIC ACID CYCLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIMERIZATION; DISSOCIATION CONSTANT; DNA SEQUENCE; DOSE RESPONSE; DRUG DESIGN; E BOX ELEMENT; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; HYDROGENATION; IC50; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOPHILICITY; OXIDATIVE PHOSPHORYLATION; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; METABOLISM; MOLECULAR LIBRARY; MOLECULAR MIMICRY; NUCLEAR MAGNETIC RESONANCE; PHARMACOLOGY; PROCEDURES; PROTEIN MULTIMERIZATION; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY TECHNIQUES, SYNTHETIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HELIX-LOOP-HELIX MOTIFS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR MIMICRY; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-MYC; SMALL MOLECULE LIBRARIES; SURFACE PLASMON RESONANCE;

EID: 84927582243     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501440q     Document Type: Article

References (78)

1. Dang, C. V. c-Myc target genes involved in cell growth, apoptosis, and metabolism Mol. Cell. Biol. 1999, 19, 1 - 11
2. Nesbit, C. E.; Tersak, J. M.; Prochownik, E. V. MYC oncogenes and human neoplastic disease Oncogene 1999, 18, 3004 - 3016
3. Coller, H. A.; Grandori, C.; Tamayo, P.; Colbert, T.; Lander, E. S.; Eisenman, R. N.; Golub, T. R. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion Proc. Natl. Acad. Sci. U. S. A. 2000, 97, 3260 - 3265
4. Trumpp, A.; Refaeli, Y.; Oskarsson, T.; Gasser, S.; Murphy, M.; Martin, G. R.; Bishop, J. M. c-Myc regulates mammalian body size by controlling cell number but not cell size Nature 2001, 414, 768 - 773
5. Eisenman, R. N. Deconstructing myc Genes Dev. 2001, 15, 2023 - 2030
6. Boxer, L. M.; Dang, C. V. Translocations involving c-myc and c-myc function Oncogene 2001, 20, 5595 - 5610
7. Pelengaris, S.; Khan, M.; Evan, G. c-MYC: more than just a matter of life and death Nature Rev. Cancer 2002, 2, 764 - 776
8. Pelengaris, S.; Khan, M. The many faces of c-MYC Arch. Biochem. Biophys. 2003, 416, 129 - 136
9. Adhikary, S.; Eilers, M. Transcriptional regulation and transformation by Myc proteins Nature Rev. Mol. Cell Biol. 2005, 6, 635 - 645
10. Meyer, N.; Penn, L. Z. Reflecting on 25 years with MYC Nature Rev. Cancer 2008, 8, 976 - 990
11. Nair, S. K.; Burley, S. K. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors Cell 2003, 112, 193 - 205
12. Amati, B.; Brooks, M. W.; Levy, N.; Littlewood, T. D.; Evan, G. I.; Land, H. Oncogenic activity of the c-Myc protein requires dimerization with Max Cell 1993, 72, 233 - 245
13. Berns, E. M.; Klijn, J. G.; van Putten, W. L.; van Staveren, I. L.; Portengen, H.; Foekens, J. A. c-Myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer Cancer Res. 1992, 52, 1107 - 1113
14. Buchholz, M.; Schatz, A.; Wagner, M.; Michl, P.; Linhart, T.; Adler, G.; Gress, T. M.; Ellenrieder, V. Overexpression of c-Myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway EMBO J. 2006, 25, 3714 - 3724
15. Mitani, S.; Kamata, H.; Fujiwara, M.; Aoki, N.; Tango, T.; Fukuchi, K.; Oka, T. Analysis of c-Myc DNA amplification in non-small cell lung carcinoma in comparison with small cell lung carcinoma using polymerase chain reaction Clin. Exp. Med. 2001, 1, 105 - 111
16. Erisman, M. D.; Rothberg, P. G.; Diehl, R. E.; Morse, C. C.; Spandorfer, J. M.; Astrin, S. M. Mol. Cell. Biol. 1985, 5, 1969 - 1976
17. Delgado, M. D.; Leon, J. Myc roles in hematopoiesis and leukemia Genes Cancer 2010, 1, 605 - 616
18. Dalla-Favera, R.; Bregni, M.; Erikson, J.; Patterson, D.; Gallo, R. C.; Croce, C. M. Human c-Myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells Proc. Natl. Acad. Sci. U. S. A. 1982, 79, 7824 - 7827
19. von Eyss, B.; Eilers, M. Addicted to Myc-but why? Genes Dev. 2011, 25, 895 - 897
20. Wang, H.; Mannava, S.; Grachtchouk, V.; Zhuang, D.; Soengas, M. S.; Gudkov, A. V.; Prochownik, E. V.; Nikiforov, M. A. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle Oncogene 2008, 27, 1905 - 1915
21. Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. Modelling Myc inhibition as a cancer therapy Nature 2008, 455, 679 - 683
22. Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W. B.; Fedorov, O.; Morse, E. M.; Keates, T.; Hickman, T. T.; Felletar, I.; Philpott, M.; Munro, S.; McKeown, M. R.; Wang, Y.; Christie, A. L.; West, N.; Cameron, M. J.; Schwartz, B.; Heightman, T. D.; La Thangue, N.; French, C. A.; Wiest, O.; Kung, A. L.; Knapp, S.; Bradner, J. E. Selective inhibition of BET bromodomains Nature 2010, 468, 1067 - 1073
23. Muller, S.; Filippakopoulos, P.; Knapp, S. Bromodomains as therapeutic targets Expert Rev. Mol. Med. 2011, 13, e29
24. Prinjha, R. K.; Witherington, J.; Lee, K. Place your BETs: the therapeutic potential of bromodomains Trends Pharmacol. Sci. 2012, 33, 146 - 153
25. Hewings, D. S.; Rooney, T. P.; Jennings, L. E.; Hay, D. A.; Schofield, C. J.; Brennan, P. E.; Knapp, S.; Conway, S. J. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions J. Med. Chem. 2012, 55, 9393 - 9413
26. Sanchez, R.; Meslamani, J.; Zhou, M. M. The bromodomain: from epigenome reader to druggable target Biochim. Biophys. Acta 2014, 1839, 676 - 685
27. Zirath, H.; Frenzel, A.; Oliynyk, G.; Segerström, L.; Westermark, U. K.; Larsson, K.; Munksgaard Persson, M.; Hultenby, K.; Lehtiö, J.; Einvik, C.; Påhlman, S.; Kogner, P.; Jakobsson, P. J.; Henriksson, M. A. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells Proc. Natl. Acad. Sci. U. S. A. 2013, 110, 10258 - 10263
28. Soucek, L.; Nasi, S.; Evan, G. I. Omomyc expression in skin prevents Myc-induced papillomatosis Cell Death. Differ. 2004, 11, 1038 - 1045
29. Annibali, D.; Whitfield, J. R.; Favuzzi, E.; Jauset, T.; Serrano, E.; Cuartas, I.; Redondo-Campos, S.; Folch, G.; Gonzàlez-Juncà, A.; Sodir, N. M.; Massó-Vallés, D.; Beaulieu, M. E.; Swigart, L. B.; McGee, M. M.; Somma, M. P.; Nasi, S.; Seoane, J.; Evan, G. I.; Soucek, L. Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis Nature Commun. 2014, 5, 4632
30. Soucek, L.; Evan, G. I. The ups and downs of Myc biology Curr. Opin. Genet. Dev. 2010, 20, 91 - 95
31. Delmore, J. E.; Issa, G. C.; Lemieux, M. E.; Rahl, P. B.; Shi, J.; Jacobs, H. M.; Kastritis, E.; Gilpatrick, T.; Paranal, R. M.; Qi, J.; Chesi, M.; Schinzel, A. C.; McKeown, M. R.; Heffernan, T. P.; Vakoc, C. R.; Bergsagel, P. L.; Ghobrial, I. M.; Richardson, P. G.; Young, R. A.; Hahn, W. C.; Anderson, K. C.; Kung, A. L.; Bradner, J. E.; Mitsiades, C. S. BET bromodomain inhibition as a therapeutic strategy to target c-Myc Cell 2011, 146, 904 - 917
32. Soucek, L.; Whitfield, J. R.; Sodir, N. M.; Masso-Valles, D.; Serrano, E.; Karnezis, A. N.; Swigart, L. B.; Evan, G. I. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice Genes Dev. 2013, 27, 504 - 513
33. Fletcher, S.; Prochownik, E. V. Small-molecule inhibitors of the Myc oncoprotein Biochim. Biophys. Acta 2014, 10.1016/j.bbagrm.2104.03.005
34. Yap, J. L.; Chauhan, J.; Jung, K.-Y.; Chen, L.; Prochownik, E. V.; Fletcher, S. Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein-protein and protein-DNA interactions MedChemComm 2012, 3, 541 - 551
35. Prochownik, E. V.; Vogt, P. K. Therapeutic Targeting of Myc Genes Cancer 2010, 1, 650 - 659
36. Yin, X.; Giap, C.; Lazo, J. S.; Prochownik, E. V. Low molecular weight inhibitors of Myc-Max interaction and function Oncogene 2003, 22, 6151 - 6159
37. Wang, H.; Hammoudeh, D. I.; Follis, A. V.; Reese, B. E.; Lazo, J. S.; Metallo, S. J.; Prochownik, E. V. Improved low molecular weight Myc-Max inhibitors Mol. Cancer Ther. 2007, 6, 2399 - 2408
38. Berg, T.; Cohen, S. B.; Desharnais, J.; Sonderegger, C.; Maslyar, D. J.; Goldberg, J.; Boger, D. L.; Vogt, P. K. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 3830 - 3835
39. Shi, J.; Strover, J. S.; Whitby, L. R.; Vogt, P. K.; Boger, D. L. Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation Bioorg. Med. Chem. Lett. 2009, 19, 6038 - 6041
40. Xu, Y.; Shi, J.; Yamamoto, N.; Moss, J. A.; Vogt, P. K.; Janda, K. D. A credit-card library approach for disrupting protein-protein interactions Bioorg. Med. Chem. 2006, 14, 2660 - 2673
41. Kiessling, A.; Sperl, B.; Hollis, A.; Eick, D.; Berg, T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules Chem. Biol. 2006, 13, 745 - 751
42. Kiessling, A.; Wiesinger, R.; Sperl, B.; Berg, T. Selective inhibition of c-Myc/Max dimerization by a pyrazolo[1,5-a]pyrimidine ChemMedChem 2007, 2, 627 - 630
43. Follis, A. V.; Hammoudeh, D. I.; Wang, H. B.; Prochownik, E. V.; Metallo, S. J. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules Chem. Biol. 2008, 15, 1149 - 1155
44. Hammoudeh, D. I.; Follis, A. V.; Prochownik, E. V.; Metallo, S. J. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc J. Am. Chem. Soc. 2009, 131, 7390 - 7401
45. Yap, J. L.; Wang, H.; Hu, A.; Chauhan, J.; Jung, K.-Y.; Gharavi, R. B.; Prochownik, E. V.; Fletcher, S. Pharmacophore identification of c-Myc inhibitor 2 Bioorg. Med. Chem. Lett. 2013, 23, 370 - 374
46. Wang, H.; Chauhan, J.; Hu, A.; Pendleton, K.; Yap, J. L.; Sabato, P. E.; Jones, J. W.; Perri, M.; Yu, J.; Cione, E.; Kane, M. A.; Fletcher, S.; Prochownik, E. V. Disruption of Myc-Max heterodimerization with improved cell-penetrating analogs of the small molecule 2 Oncotarget 2013, 4, 936 - 947
47. Chauhan, J.; Wang, H.; Yap, J. L.; Sabato, P. E.; Hu, A.; Prochownik, E. V.; Fletcher, S. Discovery of methyl 4′-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1′-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-Max dimerization ChemMedChem 2014, 9, 2274 - 2285
48. Fieber, W.; Schneider, M. L.; Matt, T.; Kräutler, B.; Konrat, R.; Bister, K. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc J. Mol. Biol. 2001, 307, 1395 - 1410
49. Ernst, J. T.; Kutzki, O.; Debnath, A. K.; Jiang, S.; Lu, H.; Hamilton, A. D. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion Angew. Chem., Int. Ed. 2002, 41, 278 - 281
50. Saraogi, I.; Hebda, J. A.; Becerril, J.; Estroff, L. A.; Miranker, A. D.; Hamilton, A. D. Synthetic alpha-helix mimetics as agonists and antagonists of islet amyloid polypeptide aggregation Angew. Chem., Int. Ed. 2010, 49, 736 - 739
51. Yap, J. L.; Cao, X.; Vanommeslaeghe, K.; Jung, K.-Y.; Wilder, P.; Nan, A.; MacKerell, A. D., Jr.; Smythe, W. R.; Fletcher, S. Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors Org. Biomol. Chem. 2012, 10, 2928 - 2933
52. Cao, X.; Yap, J. L.; Newell-Rogers, M. K.; Peddaboina, C.; Hua, J.; Papaconstantinou, H. T.; Jupitor, D.; Rai, A.; Jung, K.-Y.; Tubin, R. P.; Yu, W.; Vanommeslaeghe, K.; Wilder, P. T.; MacKerell, A. D., Jr.; Fletcher, S.; Smythe, W. R. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak Mol. Cancer 2013, 12, 42
53. Jung, K.-Y.; Vanommeslaeghe, K.; Lanning, M. E.; Yap, J. L.; Gordon, C.; Wilder, P. T.; MacKerell, A. D., Jr.; Fletcher, S. Amphipathic α-helix mimetics based on a 1,2-diphenylacetylene scaffold Org. Lett. 2013, 15, 3234 - 3237
54. Orner, B. P.; Ernst, J. T.; Hamilton, A. D. Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an α-helix J. Am. Chem. Soc. 2001, 123, 5382 - 5383
55. Plante, J. P.; Burnley, T.; Malkova, B.; Webb, M. E.; Warriner, S. L.; Edwards, T. A.; Wilson, A. J. Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction Chem. Commun. 2009, 5091 - 5093
56. Lanning, M. E.; Fletcher, S. Recapitulating the α-helix: nonpeptidic, low-molecular-weight ligands for the modulation of helix-mediated protein-protein interactions Future Med. Chem. 2013, 5, 2157 - 2174
57. Blackwood, E. M.; Eisenman, R. N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc Science 1991, 251, 1211 - 1217
58. Zhang, H.; Fan, S.; Prochownik, E. V. Distinct roles for MAX protein isoforms in proliferation and apoptosis J. Biol. Chem. 1997, 272, 17416 - 17424
59. Prochownik, E. V.; VanAntwerp, M. E. Differential patterns of DNA binding by myc and max proteins Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 960 - 964
60. Holien, T.; Vatsveen, T. K.; Hella, H.; Waage, A.; Sundan, A. Addiction to c-MYC in multiple myeloma Blood 2012, 120, 2450 - 2453
61. Mateyak, M. K.; Obaya, A. J.; Adachi, S.; Sedivy, J. M. Phenotypes of c-Myc-deficient rat fibrobasta isolated by targeted homologous recombination Cell Growth Differ. 1997, 8, 1039 - 1048
62. Graves, J. A.; Rothermund, K.; Wang, T.; Qian, W.; Van Houten, B.; Prochownik, E. V. Point mutations in c-Myc uncouple neoplastic transformation from multiple other phenotypes in rat fibroblasts PLoS One 2010, 5 (10) e13717
63. Bennett, M. R.; Anglin, S.; McEwan, J. R.; Jagoe, R.; Newby, A. C.; Evan, G. I. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-Myc antisense oligodeoxynucleotides J. Clin. Invest. 1994, 93, 820 - 828
64. Arvanitis, C.; Felsher, D. W. Conditional transgenic models define how MYC initiates and maintains tumorigenesis Semin. Cancer Biol. 2006, 16, 313 - 317
65. Wang, H.; Mannava, S.; Grachtchouk, V.; Zhuang, D.; Soengas, M. S.; Gudkov, A. V.; Prochownik, E. V.; Nikiforov, M. A. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle Oncogene 2008, 27, 1905 - 1915
66. Dang, C. V. Therapeutic targeting of Myc-reprogrammed cancer cell metabolism Cold Spring Harb. Symp. Quant. Biol. 2011, 76, 369 - 374
67. Graves, J. A.; Wang, Y.; Sims-Lucas, S.; Cherok, E.; Rothermund, K.; Branca, M. F.; Elster, J.; Beer-Stolz, D.; Van Houten, B.; Vockley, J.; Prochownik, E. V. Mitochondrial structure, function and dynamics are temporally controlled by c-Myc PLoS One 2012, 7, e37699
68. Li, F.; Wang, Y.; Zeller, K. I.; Potter, J. J.; Wonsey, D. R.; O'Donnell, K. A.; Kim, J. W.; Yustein, J. T.; Lee, L. A.; Dang, C. V. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis Mol. Cell. Biol. 2005, 25, 6225 - 6234
69. Edmunds, L. R.; Sharma, L.; Kang, A.; Lu, J.; Vockley, J.; Basu, S.; Uppala, R.; Goetzman, E. S.; Beck, M. E.; Scott, D.; Prochownik, E. V. c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate J. Biol. Chem. 2014, 10.1074/jbc.M114.580662
70. Rahl, P. B.; Lin, C. Y.; Seila, A. C.; Flynn, R. A.; McCuine, S.; Burge, C. B.; Sharp, P. A.; Young, R. A. c-Myc regulates transcriptional pause release Cell 2010, 141, 432 - 445
71. Clausen, D. M.; Guo, J.; Parise, R. A.; Beumer, J. H.; Egorin, M. J.; Lazo, J. S.; Prochownik, E. V.; Eiseman, J. L. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization J. Pharmacol. Exp. Ther. 2010, 335, 715 - 727
72. Murphy, N. S.; Prabhakaran, P.; Azzarito, V.; Plante, J. P.; Hardie, M. J.; Kilner, C. A.; Warriner, S. L.; Wilson, A. J. Solid-phase methodology for synthesis of O-alkylated aromatic oligoamide inhibitors of α-helix-mediated protein-protein interactions Chem.-Eur. J. 2013, 19, 5546 - 5550
73. Plante, J.; Campbell, F.; Malkova, B.; Kilner, C.; Warriner, S. L.; Wilson, A. J. Synthesis of functionalised aromatic oligamide rods Org. Biomol. Chem. 2008, 6, 138 - 146
74. Ferre-D'Amare, A. R.; Prendergast, G. C.; Ziff, E. B.; Burley, S. K. Recognition by Max of its cognate DNA through a dimeric b/HLH/Z domain Nature 1993, 363, 38 - 45
75. Delaglio, F.; Grzesiek, S.; Vuister, G. W.; Zhu, G.; Pfeifer, J.; Bax, A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes J. Biomol. NMR 1995, 6, 277 - 293
76. Goddard, T. D.; Kneller, D. G. SPARKY3; University of California, San Francisco: San Francisco, CA 2001.
77. Lian, L. Y.; Barsukov, I. L.; Sutcliffe, M. J.; Sze, K. H.; Roberts, G. C. Protein-ligand interactions: exchange processes and determination of ligand conformation and protein-ligand contacts Methods Enzymol. 1994, 239, 657 - 700
78. Prochownik, E. V.; Kukowska, J. Deregulated expression of c-myc by murine erythroleukaemia cells prevents differentiation Nature 1986, 322, 848 - 850